- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen, the Pharmaceutical Companies of Johnson & Johnson, Announces First-of-its-Kind Drug Donation Program for HIV Treatment-Experienced Children
Sub-Saharan African Ministries of Health Invited to Submit Expression of Interest to Participate in New EffortDonation Program to be Part of Broader Initiative to Raise Awareness and Action
New VELCADE® Data Highlight Treatment’s Versatility And Its Continued Role As A Backbone Of Multiple Myeloma Therapy
Studies affirm benefits of VELCADE (bortezomib) therapy regarding survival, disease progression, safety and quality of life in multiple myeloma, in both monotherapy and combination therapy
Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
Encouraging Data from a Phase 1b/2, Open-label, Multicenter Study
Janssen Pharmaceutica NV Extends Commitment to Global Mental Health Scholarships as Part of Its Healthy Minds Programme
Funding to British schools continues meaningful aid for future leaders in mental health research, policy and practice
New Data at American Society of Hematology (ASH) Annual Meeting Will Offer Important Insights into Safe and Efficacious Use of XARELTO®
XARELTO® is the Most Prescribed Novel Oral Anticoagulant in the U.S. Market Today
OLYSIO™ (simeprevir) Receives FDA Approval for Combination Treatment of Chronic Hepatitis C
OLYSIO™is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease
Janssen Oncology Data to be Presented at 2013 American Society of Hematology (ASH) Annual Meeting
Findings Highlight Company’s Growing Hematologic Area of Focus, Including Ibrutinib, Siltuximab and Daratumumab
IMBRUVICA™ (ibrutinib) Capsules Now Approved in the U.S. for Mantle Cell Lymphoma Patients Who Have Received at Least One Prior Therapy
Single-agent oral therapy is one of the first medications to be approved via the U.S. Food and Drug Administration’s Breakthrough Therapy Designation Pathway